

January 12, 2015



## **Pressure BioSciences, Inc. to Present at the 8th Annual OneMedForum Investor Conference - San Francisco**

SOUTH EASTON, Mass., Jan. 12, 2015 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced that Mr. Richard T. Schumacher, President and CEO, will present a corporate overview at the 8<sup>th</sup> Annual OneMedForum Investor Conference in San Francisco, CA on Monday, January 12<sup>th</sup> at 12pm PST. The Investor Conference is being held at the San Francisco Marriott Marquis.

Mr. Schumacher's presentation will be webcast and can be viewed live and up to 30 days thereafter on the following website ([www.onemedmarket.com](http://www.onemedmarket.com)).

### **About OneMedForum**

OneMedForum comes to a new venue in 2015, the San Francisco Marriott Marquis, with a range of exciting features and the longstanding objective to assemble the most innovative technologies in healthcare, life sciences, and medicine by connecting promising companies with investors and strategic partners. The venue will provide an exhibit area for networking and poster displays as well as exhibits of the latest tools in emerging healthcare, life sciences, and medical technology.

### **About Pressure BioSciences, Inc.**

Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated \$6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and forensic applications.

### **Forward Looking Statements**

Statements contained in this press release regarding PBI's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These

risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2013, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:

<http://www.pressurebiosciences.com>

Please visit us on Facebook, LinkedIn, and Twitter

**Investor Contacts:**

Richard T. Schumacher, President and CEO (508) 230-1828 (T)

Nathan P. Lawrence, VP Marketing and Sales (508) 230-1829 (F)

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/pressure-biosciences-inc-to-present-at-the-8th-annual-onemedforum-investor-conference--san-francisco-300018951.html>

SOURCE Pressure BioSciences, Inc.